Cyto-Facto Inc. announced that it has raised ¥1,180 million in a round of funding co-led by new investor MPower Partners Fund LP, a fund managed by MPower Partners GP Limited and returning investor D3 Bio Healthcare Fund, a fund managed by D3 LLC. on April 22, 2024. The transaction included participation from new investors Mitsubishi Corporation, Asahi Kasei Corporation, Mizuho Capital Co., Ltd., SMBC Venture Capital Co., Ltd., Kobe University Capital Co., Ltd. and other investors.

The company raised funding through series A third party allotment of capital. Yumiko Murakami of MPower Partners GP Limited joined board of directors as part of the transaction.